Lenalidomide Capsule
Product Images NDC 43598-511

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 43598-511). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

FDA Label Image

Container2 (Container2)

Not-Available. The given text contains errors where some words and numbers are not readable and cannot be used to generate a useful description.*

FDA Label Image

Container3 (Container3)

FDA Label Image

Container4 (Container4)

FDA Label Image

Container5 (Container5)

FDA Label Image

Container6 (Container6)

DrReddys' Lenalidomide capsules of 25mg strength with the NDC code 43598-51521 have the potential to cause birth defects in humans and comes in a package of 21 capsules. Other unclear characters and symbols are present in the text.*

FDA Label Image

Fig3 (Fig3)

This is a clinical trial result. It includes the proportion of subjects who underwent treatment with Lenalidomide/Dex and Placebo/Dex. The results show the hazard ratio (HR) and the 95% confidence interval (CI) for time to progression (months) using Log Rank analysis. The HR for the Lenalidomide/Dex group was 0.285 (95% CI: 0.210-0.386) with a statistically significant p-value of less than 0.001. The time to progression graph is also provided.*

FDA Label Image

Fig4 (Fig4)

The text describes the results of a study comparing treatment with Lenalidomide/Dex versus Placebo/Dex. The proportion of subjects in each group is unclear. The study found that Lenalidomide/Dex significantly increased time to progression compared to Placebo/Dex. The hazard ratio for Lenalidomide/Dex vs Placebo/Dex is 0.324 with 95% confidence interval (0.240-0.438). The p-value for the difference between the two groups is less than 0.001. Time to progression is plotted over 25 months.*

FDA Label Image

Figure10 (Figure10)

FDA Label Image

Figure5 (Figure5)

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Figure9 (Figure9)

This text presents statistical data from a study comparing the survival probability of patients treated with Lenalidomide or placebo. The results show that Lenalidomide has a significantly higher survival rate. The text also includes a graph showing the progression-free survival in months and the number of subjects at risk.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.